{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:40:15Z","timestamp":1787010015294,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020205","name":"Health Commission of Jiangxi Province","doi-asserted-by":"crossref","award":["SKJP220212522"],"award-info":[{"award-number":["SKJP220212522"]}],"id":[{"id":"10.13039\/501100020205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To explore the clinical features and significance of \u201cnotch\u201d in reactivation of retinopathy of prematurity (ROP) post\u2013intravitreal ranibizumab (IVR) monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Ninety-six infants (173 eyes) with Type 1 or aggressive ROP (A-ROP) post-IVR monotherapy were retrospectively analyzed; 51 eyes were notch (+) and 122 eyes were notch (\u2212). General demographics and clinical outcomes were compared by notch status for Type 1 and A-ROP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The notch primarily appeared in Stage 2 ROP (84.4% and 78.9%) at the junction of Zones I and II (68.8% and 63.2%) on the temporal side in Type 1 ROP and A-ROP. Notch was present in the Type 1 ROP group before first IVR but posttreatment in the A-ROP group. A significantly higher reactivation rate, longer follow-up duration, and postmenstrual age at the last follow-up were seen in the notch (+) versus the notch (\u2212) group. In the notch (+) ROP group, the mean gestational age (28.34 \u00b1 0.93 vs. 29.94 \u00b1 1.48 weeks) was significantly lower in reactivated versus regressed eyes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Notches appeared at different times but similar locations in Type 1 ROP and A-ROP. The reactivation rate after IVR was increased in ROP with notches. Notch may be a useful biomarker for reactivation after IVR in ROP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004231","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T16:04:43Z","timestamp":1724688283000},"page":"2168-2176","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["CHARACTERISTICS OF \u201cNOTCH\u201d IN RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL RANIBIZUMAB MONOTHERAPY"],"prefix":"10.1097","volume":"44","author":[{"given":"Fengjun","family":"Zhang","sequence":"first","affiliation":[{"name":"The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China;"},{"name":"Jiangxi Province Key Laboratory of Ophthalmology and Vision Sciences, Nanchang, China;"},{"name":"Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, China; and"},{"name":"Jiangxi Provincial Key Laboratory of Vitreoretinal Diseases for Health, Nanchang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zou","sequence":"additional","affiliation":[{"name":"The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China;"},{"name":"Jiangxi Province Key Laboratory of Ophthalmology and Vision Sciences, Nanchang, China;"},{"name":"Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, China; and"},{"name":"Jiangxi Provincial Key Laboratory of Vitreoretinal Diseases for Health, Nanchang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Liu","sequence":"additional","affiliation":[{"name":"The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China;"},{"name":"Jiangxi Province Key Laboratory of Ophthalmology and Vision Sciences, Nanchang, China;"},{"name":"Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, China; and"},{"name":"Jiangxi Provincial Key Laboratory of Vitreoretinal Diseases for Health, Nanchang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"You","sequence":"additional","affiliation":[{"name":"The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China;"},{"name":"Jiangxi Province Key Laboratory of Ophthalmology and Vision Sciences, Nanchang, China;"},{"name":"Jiangxi Clinical Research Center for Ophthalmic Disease, Nanchang, China; and"},{"name":"Jiangxi Provincial Key Laboratory of Vitreoretinal Diseases for Health, Nanchang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.semperi.2019.05.001","article-title":"Retinopathy of prematurity\u2014a world update","volume":"43","author":"Darlow","year":"2019","journal-title":"Semin Perinatol"},{"key":"R2-20250605","first-page":"233","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"911095","DOI":"10.3389\/fmed.2022.911095","article-title":"Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1,627 eyes in China","volume":"9","author":"Linghu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40272-020-00433-z","article-title":"Ranibizumab: a review in retinopathy of prematurity","volume":"23","author":"Lee","year":"2021","journal-title":"Paediatr Drugs"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International Classification of Retinopathy of Prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/ICU.0000000000000783","article-title":"Complications of retinopathy of prematurity treatment","volume":"32","author":"Barnett","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2020.12.018","article-title":"Erratum to retinopathy of prematurity: evolving treatment with anti-vascular endothelial growth factor. Am J Ophthalmol 2020;218:208\u2013213","volume":"231","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bjophthalmol-2018-312272","article-title":"Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety","volume":"103","author":"Kang","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13052-023-01543-3","article-title":"The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis","volume":"49","author":"Chen","year":"2023","journal-title":"Ital J Pediatr"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","article-title":"Comparison in retreatments between bevacizumab and ranibizumab intravitreal injections for retinopathy of prematurity: a multicenter study","volume":"130","author":"Patel","year":"2023","journal-title":"Ophthalmology"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12886-023-02886-5","article-title":"Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity","volume":"23","author":"Cao","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/IAE.0000000000002943","article-title":"Outcomes of nonconfluent diode laser panretinal photocoagulation for aggressive posterior retinopathy of prematurity after intravitreal bevacizumab","volume":"41","author":"Mammo","year":"2021","journal-title":"Retina"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1038\/s41433-021-01814-5","article-title":"Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity","volume":"36","author":"Bassiouny","year":"2022","journal-title":"Eye (Lond)."},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"Garcia Gonzalez","year":"2018","journal-title":"Retina"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/IAE.0000000000001719","article-title":"The cutting edge of retinopathy of prematurity care: expanding the boundaries of diagnosis and treatment","volume":"37","author":"Yonekawa","year":"2017","journal-title":"Retina"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jamaophthalmol.2018.4290","article-title":"Incidence and early course of retinopathy of prematurity: secondary analysis of the postnatal growth and retinopathy of prematurity (G-ROP) study","volume":"136","author":"Quinn","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1097\/IAE.0000000000003196","article-title":"Factors associated with reactivation after intravitreal bevacizumab or ranibizumab therapy in infants with retinopathy of prematurity","volume":"41","author":"Iwahashi","year":"2021","journal-title":"Retina"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"753","DOI":"10.18240\/ijo.2022.05.10","article-title":"Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity","volume":"15","author":"Zou","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaophthalmol.2022.1344","article-title":"Integrated visualization highlighting retinal changes in retinopathy of prematurity from 3-dimensional optical coherence tomography data","volume":"140","author":"Mangalesh","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/s41433-019-0500-5","article-title":"Foveal abnormalities determined by optical coherence tomography angiography in children with history of retinopathy of prematurity","volume":"33","author":"Takagi","year":"2019","journal-title":"Eye (Lond)."},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0161-6420(99)00732-0","article-title":"A small foveal avascular zone may be an historic mark of prematurity","volume":"106","author":"Mintz-Hittner","year":"1999","journal-title":"Ophthalmology"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/bjophthalmol-2012-301612","article-title":"Foveal avascular zone and foveal pit formation after preterm birth","volume":"96","author":"Yanni","year":"2012","journal-title":"Br J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T13:00:42Z","timestamp":1749128442000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004231","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]}}}